Actavis High Blood Pressure Drug Fails to Win U.S. Approval
This article is for subscribers only.
Actavis Plc failed to win U.S. approval to sell its treatment for high blood pressure that combines two heart drugs already on the market.
The Food and Drug Administration rejected the combination pill made up the active ingredients in Actavis’s Bystolic and Novartis AG’s second-best seller Diovan, Actavis said today in a statement. A panel of advisers to the FDA voted 6 to 4 in September against recommending the treatment for approval.